{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:28:38Z","timestamp":1792931318315,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Remimazolam, a benzodiazepine, was first approved in 2020 for general anesthesia and procedural sedation but has not for sedation in the intensive care units. As other sedatives used in intensive care units have disadvantages such as propofol infusion syndrome and hypotension, an alternative sedative would be desired.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Remimazolam was developed as a soft drug that is designed to be rapidly metabolized to the inactive chemical, CNS7054. In humans, it is mainly metabolized by the non-specific esterase, carboxylesterase 1, in the liver, not in the blood, unlike the ultrashort-acting soft drug remifentanil. Remimazolam is a short-acting drug. The context-sensitive decrement time, which describes how the accumulated drug affects the decay curve of the drug concentration after its infusion ends, of remimazolam is similar to that of propofol. Remimazolam binds the benzodiazepine site of the gamma-aminobutyric acid type A receptors, and does not directly activate the gamma-aminobutyric acid type A receptors. Benzodiazepines are not effective in the absence of gamma-aminobutyric acid. Although hypotension appears less frequent, it can occur during remimazolam administration. Delayed emergence can occur after remimazolam infusion due to its accumulation. To prevent delayed emergence, excessive doses should be avoided. A dose of the competitive antagonist flumazenil can cause re-sedation after administration. The impact of delirium after prolonged sedation is unknown. The remimazolam concentration at steady-state is approximately 10% higher in males than in females,\u2009&gt;\u200920% in obese patients than in normal weight patients, and approximately 20% higher in American Society of Anesthesiologists physical status III\/IV patients than in I\/II patients. The infusion rate should may be reduced in these patients. A study has shown that the required dose is higher in children than in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Remimazolam could be an alternative sedative in intensive care units. Because remimazolam is short-acting, it accumulates during prolonged infusions. Infusion rate should be titrated based on patient characteristics, including sex, body mass index, and physical status. Benzodiazepine tolerance should be considered before and during remimazolam infusion. Similar to other sedatives, concurrent use of additional hypnotics and analgesics may help maintain the desired sedation in intensive care units.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40560-026-00858-7","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:16:52Z","timestamp":1770819412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological profiles and mechanism of action of remimazolam for ICU sedation"],"prefix":"10.1186","volume":"14","author":[{"given":"Kenichi","family":"Masui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00134-022-06712-2","volume":"48","author":"K Lewis","year":"2022","unstructured":"Lewis K, Alshamsi F, Carayannopoulos KL, Granholm A, Piticaru J, Al Duhailib Z, et al. Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2022;48:811\u201340.","journal-title":"Intensive Care Med"},{"key":"858_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00000542-199203000-00003","volume":"76","author":"MA Hughes","year":"1992","unstructured":"Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiol. 1992;76:334\u201341.","journal-title":"Anesthesiol"},{"key":"858_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jclinane.2010.09.006","volume":"23","author":"MA Fr\u00f6lich","year":"2011","unstructured":"Fr\u00f6lich MA, Arabshahi A, Katholi C, Prasain J, Barnes S. Hemodynamic characteristics of midazolam, propofol, and dexmedetomidine in healthy volunteers. J Clin Anesth. 2011;23:218\u201323.","journal-title":"J Clin Anesth"},{"key":"858_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2044.2007.05055.x","volume":"62","author":"PCA Kam","year":"2007","unstructured":"Kam PCA, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62:690\u2013701.","journal-title":"Anaesthesia"},{"key":"858_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1112-5","volume":"19","author":"A Krajcova","year":"2015","unstructured":"Krajcova A, Waldauf P, Andel M, Duska F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19:398.","journal-title":"Crit Care"},{"key":"858_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/bjaed\/mkv047","volume":"16","author":"VL Scott-Warren","year":"2016","unstructured":"Scott-Warren VL, Sebastian J. Dexmedetomidine: its use in intensive care medicine and anaesthesia. BJA Educ. 2016;16:242\u20136.","journal-title":"BJA Educ"},{"key":"858_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.bja.2022.06.020","volume":"129","author":"K Heybati","year":"2022","unstructured":"Heybati K, Zhou F, Ali S, Deng J, Mohananey D, Villablanca P, et al. Outcomes of dexmedetomidine <em>versus<\/em> propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2022;129:515\u201326.","journal-title":"Br J Anaesth"},{"key":"858_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00540-020-02755-1","volume":"34","author":"K Masui","year":"2020","unstructured":"Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!! J Anesth. 2020;34:479\u201382.","journal-title":"J Anesth"},{"key":"858_CR9","unstructured":"PAION AR # 2021: Annual Report of PAION AG [Available from: https:\/\/www.paion.com\/fileadmin\/user_upload\/GB2021_EN.pdf."},{"key":"858_CR10","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001460","volume":"15","author":"H Yoshikawa","year":"2021","unstructured":"Yoshikawa H, Hosokawa M, Kashima Y, Oki S, Masui K. Remimazolam tolerance in long-term benzodiazepine users: a case report of 2 cases. A&A Practice. 2021;15:e01460.","journal-title":"A&A Practice"},{"key":"858_CR11","volume":"15","author":"A Kitaura","year":"2023","unstructured":"Kitaura A, Hamasaki S, Sakamoto H, Tsukimoto S, Nakajima Y. Two cases of inadequate response to remimazolam. Cureus. 2023;15:e42576.","journal-title":"Cureus"},{"key":"858_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00540-022-03139-3","volume":"37","author":"K Kida","year":"2023","unstructured":"Kida K, Taguchi M, Uchiyama K, Fujioka S, Tsubokawa T. Tolerance to remimazolam at a high effect-site concentration. J Anesth. 2023;37:168\u20139.","journal-title":"J Anesth"},{"key":"858_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/ALN.0000000000004811","volume":"140","author":"R Vellinga","year":"2024","unstructured":"Vellinga R, Koomen JV, Eleveld DJ, St\u00f6hr T, Pesic M, Struys M, et al. Target-controlled infusion of remimazolam in healthy volunteers shows some acute tolerance. Anesth. 2024;140:207\u201319.","journal-title":"Anesth"},{"key":"858_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/0113892002301026240318060307","volume":"25","author":"S Wolfgang","year":"2024","unstructured":"Wolfgang S, Karl-Uwe P, Marija P, Thomas S. The metabolism of the new benzodiazepine remimazolam. Curr Drug Metab. 2024;25:164\u201373.","journal-title":"Curr Drug Metab"},{"key":"858_CR15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","volume":"70","author":"B Li","year":"2005","unstructured":"Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol. 2005;70:1673\u201384.","journal-title":"Biochem Pharmacol"},{"key":"858_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00228-019-02800-3","volume":"76","author":"X-y Sheng","year":"2020","unstructured":"Sheng X-y, Liang Y, Yang X-y, Li L-e, Ye X, Zhao X, et al. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76:383\u201391.","journal-title":"Eur J Clin Pharmacol"},{"key":"858_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bja\/67.1.41","volume":"67","author":"B Marsh","year":"1991","unstructured":"Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth. 1991;67:41\u20138.","journal-title":"Br J Anaesth"},{"key":"858_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00540-022-03079-y","volume":"36","author":"K Masui","year":"2022","unstructured":"Masui K, St\u00f6hr T, Pesic M, Tonai T. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. J Anesth. 2022;36:493\u2013505.","journal-title":"J Anesth"},{"key":"858_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00540-022-03099-8","volume":"36","author":"K Masui","year":"2022","unstructured":"Masui K, Hagihira S. Equilibration rate constant, ke0, to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. J Anesth. 2022;36:757\u201362.","journal-title":"J Anesth"},{"key":"858_CR20","first-page":"10","volume":"86","author":"CF Minto","year":"1997","unstructured":"Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I Model dev Anesthesiol. 1997;86:10\u201323.","journal-title":"I Model dev Anesthesiol"},{"key":"858_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0378-4274(98)00188-X","volume":"100\u2013101","author":"BA Orser","year":"1998","unstructured":"Orser BA, McAdam LC, Roder S, MacDonald JF. General anaesthetics and their effects on GABAA receptor desensitization. Toxicol Lett. 1998;100\u2013101:217\u201324.","journal-title":"Toxicol Lett"},{"key":"858_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.31887\/DCNS.2002.4.3\/hmoehler","volume":"4","author":"H M\u00f6hler","year":"2002","unstructured":"M\u00f6hler H. Pathophysiological aspects of diversity in neuronal inhibition: a new benzodiazepine pharmacology. Dialogues Clin Neurosci. 2002;4:261\u20139.","journal-title":"Dialogues Clin Neurosci"},{"key":"858_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04760-8","volume":"27","author":"Y Tang","year":"2023","unstructured":"Tang Y, Gao X, Xu J, Ren L, Qi H, Li R, et al. Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study. Crit Care. 2023;27:474.","journal-title":"Crit Care"},{"key":"858_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bja.2024.04.013","volume":"133","author":"R Takaki","year":"2024","unstructured":"Takaki R, Yokose M, Mihara T, Saigusa Y, Tanaka H, Yamamoto N, et al. Hypotension after general anaesthesia induction using remimazolam or propofol in geriatric patients undergoing sevoflurane anaesthesia with remifentanil: a single-centre, double-blind, randomised controlled trial. Br J Anaesth. 2024;133:24\u201332.","journal-title":"Br J Anaesth"},{"key":"858_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/anae.16205","volume":"79","author":"J Fechner","year":"2024","unstructured":"Fechner J, El-Boghdadly K, Spahn DR, Motsch J, Struys MMRF, Duranteau O, et al. Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol: a multicentre randomised controlled trial. Anaesthesia. 2024;79:410\u201322.","journal-title":"Anaesthesia"},{"key":"858_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00540-022-03107-x","volume":"37","author":"K Masui","year":"2023","unstructured":"Masui K. Caution!! Reappearance of remimazolam effect after a flumazenil bolus: a larger bolus of flumazenil and a lower total remimazolam clearance are higher risks. J Anesth. 2023;37:1\u20135.","journal-title":"J Anesth"},{"key":"858_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-021-02915-x","volume":"35","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth. 2021;35:322.","journal-title":"J Anesth"},{"key":"858_CR28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-199008000-00003","volume":"10","author":"DA Chernik","year":"1990","unstructured":"Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. Validity and reliability of the observer\u2019s: assessment of alertness\/sedation scale: study with: intravenous midazolam. J Clin Psychopharmacol. 1990;10:244\u201351.","journal-title":"J Clin Psychopharmacol"},{"key":"858_CR29","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","volume":"132","author":"J Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiol. 2020;132:636\u201351.","journal-title":"Anesthesiol"},{"key":"858_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bja.2022.02.040","volume":"129","author":"D Chae","year":"2022","unstructured":"Chae D, Kim HC, Song Y, Choi YS, Han DW. Pharmacodynamic analysis of intravenous bolus remimazolam for loss of consciousness in patients undergoing general anaesthesia: a randomised, prospective, double-blind study. Br J Anaesth. 2022;129:49\u201357.","journal-title":"Br J Anaesth"},{"key":"858_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/bjaceaccp\/mkv018","volume":"16","author":"M Narayanan","year":"2016","unstructured":"Narayanan M, Venkataraju A, Jennings J. Analgesia in intensive care: part 1. BJA Educ. 2016;16:72\u20138.","journal-title":"BJA Educ"},{"key":"858_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00540-020-02776-w","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020;34:491\u2013501.","journal-title":"J Anesth"},{"key":"858_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/ALN.0000000000003102","volume":"132","author":"A Eisenried","year":"2020","unstructured":"Eisenried A, Schuttler J, Lerch M, Ihmsen H, Jeleazcov C. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of electroencephalogram effects. Anesthesiol. 2020;132:652\u201366.","journal-title":"Anesthesiol"},{"key":"858_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109899","volume":"66","author":"J Zhou","year":"2020","unstructured":"Zhou J, Leonowens C, Ivaturi VD, Lohmer LL, Curd L, Ossig J, et al. Population pharmacokinetic\/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020;66:109899.","journal-title":"J Clin Anesth"},{"key":"858_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bja.2025.02.038","volume":"135","author":"DJ Eleveld","year":"2025","unstructured":"Eleveld DJ, Colin PJ, den Van Berg JP, Koomen JV, Stoehr T, Struys MMRF. Development and analysis of a remimazolam pharmacokinetics and pharmacodynamics model with proposed dosing and concentrations for anaesthesia and sedation. Br J Anaesth. 2025;135:206\u201317.","journal-title":"Br J Anaesth"},{"key":"858_CR36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.bja.2023.08.019","volume":"131","author":"YQ Gao","year":"2023","unstructured":"Gao YQ, Ihmsen H, Hu ZY, Sun W, Fang YB, Wang Z, et al. Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children. Br J Anaesth. 2023;131:914\u201320.","journal-title":"Br J Anaesth"},{"key":"858_CR37","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/bcp.16031","volume":"90","author":"TG van Gelder","year":"2024","unstructured":"van Gelder TG, van Diem-Zaal IJ, Dijkstra-Kersten SMA, de Mul N, Lalmohamed A, Slooter AJC. The risk of delirium after sedation with propofol or midazolam in intensive care unit patients. Br J Clin Pharmacol. 2024;90:1471\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"858_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2024.111735","volume":"101","author":"M Suga","year":"2025","unstructured":"Suga M, Yasuhara J, Watanabe A, Takagi H, Kuno T, Nishimura T, et al. Postoperative delirium under general anaesthesia by remimazolam versus propofol: a systematic review and meta-analysis of randomised controlled trials. J Clin Anesth. 2025;101:111735.","journal-title":"J Clin Anesth"},{"key":"858_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-025-03018-w","volume":"25","author":"C Li","year":"2025","unstructured":"Li C, Wei L, Gong H, Yuan X. Incidence and predictors of postoperative delirium following remimazolam administration: a systematic review and meta-analysis of 29 randomized trials. BMC Anesthesiol. 2025;25:201.","journal-title":"BMC Anesthesiol"},{"key":"858_CR40","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Kawashima S, Makino H, Doi M, Nakajima Y (2022) A comparison of remimazolam and propofol for postoperative nausea and vomiting: A propensity score-matched, observational, single-center cohort study. Korean journal of anesthesiology","DOI":"10.4097\/kja.22441"},{"key":"858_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12630-024-02900-4","volume":"72","author":"S Harimochi","year":"2025","unstructured":"Harimochi S, Godai K, Nakahara M, Matsunaga A. Comparison of remimazolam and sevoflurane for general anesthesia during transcatheter aortic valve implantation: a randomized trial. Can J Anaesth. 2025;72:397\u2013408.","journal-title":"Can J Anaesth"},{"key":"858_CR42","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s12630-024-02735-z","volume":"71","author":"S Yim","year":"2024","unstructured":"Yim S, Choi CI, Park I, Koo BW, Oh AY, Song I-A. Remimazolam to prevent hemodynamic instability during catheter ablation under general anesthesia: a randomized controlled trial. Can J of Anesth\/J canadien d\u2019anesth\u00e9sie. 2024;71:1067\u201377.","journal-title":"Can J of Anesth\/J canadien d'anesth\u00e9sie"},{"key":"858_CR43","first-page":"12","volume":"1","author":"P Wang","year":"2025","unstructured":"Wang P, Chen D, Yu H, Sun Y, Xiong J. Remimazolam provides better hemodynamic stability than propofol in hypertensive surgical patients: a randomized single-blinded trial. J Anesth. 2025;1:12.","journal-title":"J Anesth"},{"key":"858_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02249-z","volume":"23","author":"Q Xu","year":"2023","unstructured":"Xu Q, Wu J, Shan W, Duan G, Lan H. Effects of remimazolam combined with sufentanil on hemodynamics during anesthetic induction in elderly patients with mild hypertension undergoing orthopedic surgery of the lower limbs: a randomized controlled trial. BMC Anesthesiol. 2023;23:311.","journal-title":"BMC Anesthesiol"},{"key":"858_CR45","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1213\/ANE.0000000000006861","volume":"139","author":"S-H Lee","year":"2024","unstructured":"Lee S-H, Nam J-S, Choi D-K, Chin J-H, Choi I-C, Kim K. Efficacy of single-bolus administration of remimazolam during induction of anesthesia in patients undergoing cardiac surgery: a prospective, single-center, randomized controlled study. Anesth Analg. 2024;139:770\u201380.","journal-title":"Anesth Analg"},{"key":"858_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4097\/kja.24537","volume":"78","author":"JJ Min","year":"2025","unstructured":"Min JJ, Oh EJ, Hwang HJ, Jo S, Cho H, Kim C, et al. Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting. Korean J Anesthesiol. 2025;78:139\u201347.","journal-title":"Korean J Anesthesiol"},{"key":"858_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1460-9592.1998.00282.x","volume":"8","author":"Bray,","year":"1998","unstructured":"Bray,. Propofol infusion syndrome in children. Pediatr Anesth. 1998;8:491\u20139.","journal-title":"Pediatr Anesth"},{"key":"858_CR48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","volume":"122","author":"S Hemphill","year":"2019","unstructured":"Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122:448\u201359.","journal-title":"Br J Anaesth"},{"issue":"1","key":"858_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s44253-025-00091-4","volume":"3","author":"DJ Zorko","year":"2025","unstructured":"Zorko DJ, Klowak JA, Vu M, Mayer YM, Pysklywec A, Lewis K, et al. Efficacy and safety of analgosedation with dexmedetomidine in critically ill mechanically ventilated children: a systematic review and meta-analysis of randomized controlled trials. Intensive Care Med-Paediatr and Neonatal. 2025;3(1):30.","journal-title":"Intensive Care Med-Paediatr and Neonatal"},{"key":"858_CR50","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.bja.2025.02.004","volume":"134","author":"Y-H Cai","year":"2025","unstructured":"Cai Y-H, Dong L-Q, Zhong JW, Lin Z, Chen C-D, Zhu L-B, et al. ED50 and ED95 of remimazolam for loss of consciousness in young children: a dose-finding study for induction of anaesthesia. Br J Anaesth. 2025;134:1709\u201316.","journal-title":"Br J Anaesth"},{"key":"858_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/anae.16475","volume":"80","author":"Y-B Fang","year":"2025","unstructured":"Fang Y-B, Zhong JW, Szmuk P, Lyu Y-L, Xu Y, Qu S, et al. Safety and efficacy of remimazolam tosilate for general anaesthesia in paediatric patients undergoing elective surgery: a multicentre, randomised, single-blind, controlled trial. Anaesthesia. 2025;80:259\u201368.","journal-title":"Anaesthesia"},{"key":"858_CR52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00540-024-03395-5","volume":"38","author":"M Hosokawa","year":"2024","unstructured":"Hosokawa M, Takahashi Y, Ueno T, Oe K, Masui K. Remimazolam anesthesia in pediatric patients undergoing cardiac catheterization for congenital heart disease: a retrospective observational study. J Anesth. 2024;38:796\u2013805.","journal-title":"J Anesth"},{"key":"858_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","volume":"127","author":"T St\u00f6hr","year":"2021","unstructured":"St\u00f6hr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127:415\u201323.","journal-title":"Br J Anaesth"},{"key":"858_CR54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bja.2022.09.006","volume":"129","author":"A Singal","year":"2022","unstructured":"Singal A, Naftalovich R, Syed AR, Chaudhry FA, Discepola PJ, Rodriguez-Correa DT. Delayed emergence after remimazolam induction in end-stage liver disease. Br J Anaesth. 2022;129:6.","journal-title":"Br J Anaesth"},{"key":"858_CR55","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1213\/01.ANE.0000148695.37190.34","volume":"100","author":"DT Wong","year":"2005","unstructured":"Wong DT, Lai K, Chung FF, Ho RY. Cannot intubate\u2013cannot ventilate and difficult intubation strategies: results of a Canadian national survey. Anesth Analg. 2005;100:1439\u201346.","journal-title":"Anesth Analg"},{"key":"858_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s40981-023-00638-4","volume":"9","author":"S Sekimoto","year":"2023","unstructured":"Sekimoto S, Kiyama S, Uezono S. Successful reversal of remimazolam anesthesia in a \u201ccannot intubate, can ventilate\u201d situation: a case report. JA Clinical Reports. 2023;9:46.","journal-title":"JA Clinical Reports"},{"issue":"3","key":"858_CR57","first-page":"101510","volume":"44","author":"N Grillot","year":"2025","unstructured":"Grillot N, Vourc\u2019h M, Hourmant Y, Bouras M, Rozec B, Rouhani A, et al. A phase 2 open-label pilot study of Remimazolam for sedation in critically ill patients. Anaesth Crit Care and Pain Med. 2025;44(3):101510.","journal-title":"Anaesth Crit Care and Pain Med"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-026-00858-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:02:03Z","timestamp":1773799323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40560-026-00858-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1186\/s40560-026-00858-7","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}